Wells Fargo & Company Forecasts Strong Price Appreciation for Envista (NYSE:NVST) Stock

Envista (NYSE:NVST) had its target price lifted by equities research analysts at Wells Fargo & Company from $21.00 to $26.00 in a report issued on Friday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s target price points to a potential downside of 8.99% from the company’s previous close.

A number of other equities research analysts have also issued reports on NVST. Barclays began coverage on shares of Envista in a report on Monday, December 8th. They set an “overweight” rating and a $24.00 price objective for the company. Morgan Stanley set a $19.00 price objective on Envista in a research note on Friday. JPMorgan Chase & Co. upped their price target on shares of Envista from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, December 16th. Piper Sandler reiterated a “neutral” rating and issued a $25.00 target price (up previously from $21.00) on shares of Envista in a research note on Friday. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Envista in a report on Monday, December 29th. Seven analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Envista has a consensus rating of “Hold” and an average price target of $25.77.

Envista Stock Performance

NYSE NVST traded up $3.86 during trading hours on Friday, hitting $28.57. The company’s stock had a trading volume of 4,920,404 shares, compared to its average volume of 3,030,070. Envista has a 12 month low of $14.22 and a 12 month high of $28.80. The company’s 50 day simple moving average is $22.63 and its two-hundred day simple moving average is $21.16. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.37 and a quick ratio of 2.02. The company has a market cap of $4.70 billion, a P/E ratio of 317.10, a price-to-earnings-growth ratio of 1.05 and a beta of 1.01.

Envista (NYSE:NVST) last released its quarterly earnings results on Thursday, February 5th. The company reported $0.38 EPS for the quarter, beating the consensus estimate of $0.32 by $0.06. Envista had a net margin of 0.58% and a return on equity of 5.90%. The firm had revenue of $750.60 million during the quarter, compared to analyst estimates of $680.26 million. During the same quarter in the prior year, the firm earned $0.24 EPS. The business’s revenue for the quarter was up 15.0% compared to the same quarter last year. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. As a group, sell-side analysts expect that Envista will post 1 EPS for the current fiscal year.

Institutional Investors Weigh In On Envista

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Farther Finance Advisors LLC increased its holdings in shares of Envista by 317.6% during the third quarter. Farther Finance Advisors LLC now owns 1,349 shares of the company’s stock valued at $27,000 after acquiring an additional 1,026 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its position in Envista by 16,711.1% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 1,513 shares of the company’s stock worth $31,000 after purchasing an additional 1,504 shares during the last quarter. Allworth Financial LP raised its holdings in shares of Envista by 75.4% in the fourth quarter. Allworth Financial LP now owns 1,805 shares of the company’s stock worth $39,000 after buying an additional 776 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Envista by 73.1% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,248 shares of the company’s stock worth $44,000 after buying an additional 949 shares during the last quarter. Finally, IFP Advisors Inc lifted its stake in shares of Envista by 102.9% during the fourth quarter. IFP Advisors Inc now owns 2,112 shares of the company’s stock worth $46,000 after buying an additional 1,071 shares during the period.

Trending Headlines about Envista

Here are the key news stories impacting Envista this week:

• Positive Sentiment: Company press release: Envista reported Q4 2025 results showing the EPS and revenue beat and provided the new FY‑2026 EPS guidance that topped Street expectations. Envista Reports Fourth Quarter 2025 Results
• Positive Sentiment: Earnings beat summary: Analysts note Envista topped Q4 estimates on both EPS ($0.38 vs $0.32) and revenue, a core reason for the bullish reaction. Envista (NVST) Tops Q4 Earnings and Revenue Estimates
• Positive Sentiment: Market reaction coverage: Reports highlight the stock surge after the beat and the company’s “strong guidance,” reinforcing investor enthusiasm. Envista Holdings soars after beating Q4 estimates, issues strong guidance
• Neutral Sentiment: Quarter snapshot pieces summarize the beat and provide quick financials for traders and shorter‑term investors. Envista: Q4 Earnings Snapshot
• Neutral Sentiment: Deeper metric analysis: Coverage compares key Q4 metrics versus estimates and year‑ago values — useful for assessing sustainability of margin and revenue trends. Envista (NVST) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
• Neutral Sentiment: Investor resources: Conference call, slide deck and the formal press release are available for investors who want the management commentary behind the guide. View Press Release / Slide Deck
• Negative Sentiment: Valuation and profitability caveat: despite the beat, Envista’s trailing P/E is high and net margin remains thin, which could moderate upside if growth slows or guidance proves optimistic.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.